Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 concurrent pemetrexed + carboplatin + radiotherapy for limited-stage small cell lung cancer
2007-000913-13Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2007
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed and carboplatin in small cell lung cancer (SCLC), sponsored by Eli Lilly and Company. Primary endpoint: Overall response rate. Started Apr 2007; status: completed.
02
Drugs
pemetrexedcarboplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2007-000913-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000913-13.